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R E V I EW A R T I C L E
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Abstract: The proliferative endothelial and smooth muscle cell phenotype, inﬂammation, and pulmonary vascular remodeling are prom-
inent features of pulmonary arterial hypertension (PAH). Mutations in bone morphogenetic protein type 2 receptor (BMPR2) have been
identiﬁed as the most common genetic cause of PAH and females with BMPR2 mutations are 2.5 times as likely to develop heritable
forms of PAH than males. Higher levels of estrogen have also been observed in males with PAH, implicating sex hormones in PAH path-
ogenesis. Recently, the estrogen metabolite 16α-OHE1 (hydroxyestrone) was implicated in the regulation of miR29, a microRNA involved
in modulating energy metabolism. In females, decreased miR96 enhances serotonin’s effect by upregulating the 5-hydroxytryptamine 1B
(5HT1B) receptor. Because PAH is characterized as a quasi-malignant disease, likely due to BMPR2 loss of function, altered signaling path-
ways that sustain this cancer-like phenotype are being explored. Extracellular signal–regulated kinases 1 and 2 and p38 mitogen-activated protein
kinases (MAPKs) play a critical role in proliferation and cell motility, and dysregulated MAPK signaling is observed in various experimen-
tal models of PAH. Wnt signaling pathways preserve pulmonary vascular homeostasis, and dysregulation of this pathway could contribute
to limited vascular regeneration in response to injury. In this review, we take a closer look at sex, sex hormones, and the interplay between
sex hormones and microRNA regulation. We also focus on MAPK and Wnt signaling pathways in the emergence of a proproliferative, anti-
apoptotic endothelial phenotype, which then orchestrates an angioproliferative process of vascular remodeling, with the hope of developing
novel therapies that could reverse the phenotype.
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Pulmonary arterial hypertension (PAH) is a rare disorder character-
ized by endothelial cell proliferation, pulmonary vascular remodeling,
pruning of distal vessels, and increased pulmonary resistance, culmi-
nating in right heart failure and death.1 Although the initial mech-
anisms responsible for the development of idiopathic PAH (IPAH)
and other forms of PAH remain unknown, loss of normal bone mor-
phogenetic protein type 2 receptor (BMPR2) function has been im-
plicated in the formation of plexogenic lesions.2 These plexogenic le-
sions are believed to be a result of dysregulated angiogenesis, with
proliferation of endothelial cells, vascular smooth muscle cells, myo-
ﬁbroblasts, and inﬂammatory cells in and around occluded pulmo-
nary arteries.3
PAH develops more predominately in women than in men; sur-
vival is, however, poorer in men. These sex differences are incom-
pletely understood. Female predominance suggests that sex hor-
mones contributes to pulmonary vascular remodeling, in part through
the ability of estrogen (E2) to reduce BMPR2 expression.4 However,
in some experimental models of PAH (monocrotaline and chronic
hypoxia), E2 appears to protect against PAH,5 while others have
reported that endogenous E2 results in the development of experi-
mental PAH.6,7 It is thought that survival is poorer in men because
men may either respond less well to therapy or have poorer right
ventricular compensation in the face of elevated pulmonary pres-
sures than women, although neither theory has been proven. PAH
is now more frequently diagnosed in elderly patients, resulting in a
mean age at diagnosis between 50 ± 14 and 65 ± 15 years in current
registries.8 Female predominance is quite variable among registries
and may also not be present in elderly patients.9 A clearer understand-
ing, however, of how the levels of E2, E2 metabolites, and E2 re-
ceptors play a role in the pathogenesis of PAH is needed.
PAH phenotypically is characterized as a quasi-malignant disease,
and there have been many studies identifying aberrant signaling
pathways in the development of PAH, including mitogen-activated
protein kinase (MAPK) and Wnt signaling. There is increasing ev-
idence that the activation of MAPKs controls the hyperprolifera-
tion and increased motility of endothelial cells and smooth muscle
cells (SMCs) and targeted inhibition of MAPKs reverses the pheno-
type. However, some receptor tyrosine kinase (RTK) inhibitors have
paradoxically resulted in the development of PAH, so safer and more
targeted therapies must be developed. The Wnt signaling pathways,
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Wnt/β-catenin and Wnt/PCP (planar cell polarity), play a crucial role
in cell fate determination and vascular regeneration in response to in-
jury, and constitutive activation of these signaling pathways in PAH
could promote cell survival and protect against vascular remodeling.10
Here we review the role of sex and dysregulated signaling pathways
in PAH, with the hope of better understanding the complexity of this
disease.
THE ROLE OF E2 AND E2 METABOLITES IN PAH
IPAH and heritable forms of PAH (hPAH) have a mean age at
diagnosis of 35 years and a median survival of 2.8 years untreated.
Survival is not greatly improved by treatment, and there is an un-
met clinical need for effective therapeutic approaches. Epidemiolog-
ical studies report a greater incidence of the disease in females; the
female-to-male ratio can be as great as 4 ∶ 1.8,11 The reasons for this in-
creased frequency in females are unclear. Pulmonary artery smooth
muscle cells (PASMCs) normally exhibit low rates of proliferation, mi-
gration, and apoptosis to maintain a low-resistance pulmonary circu-
lation. However, alterations in signaling pathways can lead to abnor-
mal proliferation, apoptosis, and migration, and the most important
signaling pathway to this effect is the BMPR2 pathway. The primary
genetic defect of hPAH (present in at least 70% of cases of hPAH) is
a mutation in the gene encoding BMPR2.12,13 Females with mutations
are about 2.5 times as likely to develop hPAH as males.14 Heritable
PAH transmits as an autosomal dominant trait that exhibits genetic
anticipation but also markedly reduced penetrance (20%–40%).14 The
cause of the reduced penetrance is likely to be related to the need for
a “second hit” caused by environmental and/or genetic modiﬁers.
BMPR2 is a member of the transforming growth factor beta (TGF-β)
superfamily. Signaling by bone morphogenetic protein (BMP) receptors
involves heterodimerization of two transmembrane serine/threonine
kinases: the constitutively active type 2 receptor BMPR2 and a corre-
sponding type 1 receptor, BMPR1A or BMPR1B. Activated BMPR1 re-
ceptors phosphorylate a set of BMP-restricted Smad proteins (Smad1,
5, and 8), which then complex with the common partner Smad, Smad4
(Co-Smad), and translocate into the nucleus to regulate transcription
of target genes in a tissue- and cell-speciﬁc manner. The proteins in
the inhibitor of DNA binding (Id) family (Id1–Id4) are transcriptional
targets of the BMP signaling. These proteins bind with high afﬁnity to
the E-protein subfamily of basic-loop-helix family of transcription fac-
tors and inhibit their binding to target DNA, regulating gene expres-
sion and cellular differentiation. Dysfunctional Smad signaling leads to
abnormal cell proliferation associated with pulmonary vascular dis-
ease.15 Recently, higher levels of E2 were associated with PAH in men,
and it is thought that sex-based differences in sex hormone process-
ing and signaling may contribute to unique phenotypes in pulmo-
nary vascular disease.16
E2 synthesis and metabolism
In premenopausal women, E2 synthesis occurs mainly in the ovarian
follicles and corpus luteum; in postmenopausal women and men, ad-
ipose tissue is a major source of E2 synthesis.17 Aromatase (CYP19A1)
is a member of the cytochrome P450 (CYP) superfamily and syn-
thesizes E2 through the aromatization of androgens, speciﬁcally testos-
terone and androstenedione. Further metabolism is mediated by sev-
eral CYP enzymes. In particular, CYP1B1 catalyzes the oxidation of
estrone (E1)/17β-estradiol (E2) to 2- and 4-OHE2 (2- and 4-hydroxy-
estradiol). E2 hydroxylation can occur by CYP enzymes (including
CYP1B1), resulting in 6, 7, 15, and 16(α- and β-)hydroxyestradiol.
E2 can also be converted to (1) E1 by 17β-HSD (hydroxysteroid de-
hydrogenase) and hence via oxidation to 16α-OHE1 (hydroxyes-
trone), which is mitogenic, and (2) 2-OHE2 by CYP1A1/2, CYP1B1,
and CYP3A4. Catechol-O-methyltransferase (COMT) catalyzes the
methylation of catechol E2s to methoxy E2s (MEs), which simulta-
neously lowers the potential for DNA damage and increases the con-
centration of 2ME, an antiproliferative metabolite (Fig. 1).
E2 receptors and BMPR2 signaling
The effects of E2 are primarily mediated by activation of the E2
receptors ERα and ERβ, and these effects can be both genomic and
nongenomic. Very rapid, nongenomic effects of E2 have also been
described through activation of the G-protein coupled E2 receptor
(GPER). All three receptor types are expressed in human pulmo-
nary arteries, and it is thought that E2 may suppress BMPR2 ex-
pression via the receptor ERα.4 ERα is highly expressed in female
human PASMCs (hPASMCs) from PAH patients and mediates E2-
induced proliferation of hPASMCs via MAPK and Akt signaling.18
The ERα antagonist MPP (methyl-piperidino-pyrazole) protects against
hypoxia-induced pulmonary hypertension (PH) in female mice and
reverses PH in mice overexpressing the serotonin transporter (SERT+
mice) via rescue of BMPR2 signaling.7,18
E2 synthesis and BMPR2 signaling
Two promoter single-nucleotide polymorphisms (SNPs) in the gene
coding for aromatase that result in elevated E2 production have been
Figure 1. Summary of estrogen (E2) synthesis and metabolic pathways
of key interest. See text for details. COMT: catechol-O-methyltransferase;
CYP: cytochrome P450; HSD: hydroxysteroid dehydrogenase; OHE1:
hydroxyestrone.
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associated with an increased risk of portopulmonary hypertension.19
The human pulmonary artery can synthesize E2; aromatase expression
is present in the medial layer of human pulmonary arteries, and female
hPASMCs have higher aromatase expression.7 The aromatase inhibi-
tor anastrozole reversed pulmonary vascular remodeling, PH, and right
ventricular hypertrophy observed in hypoxic mice and in the Sugen/
hypoxic rat, but only in females in both models of PAH.7 The thera-
peutic effects correlated with decreases in plasma E2 levels. BMPR2
signaling is depressed in lungs from female hypoxic mice and Sugen/
hypoxic rats, and anastrozole restores these levels to normal.7 This
suggests that pulmonary arterial endogenous E2 in females can de-
press BMPR2 signaling and may contribute to the development of
PAH. This is consistent with E2 suppressing BMPR2 expression via
the ERα receptor.4 Compared to those of males, female non-PAH
hPASMCs exhibit reduced messenger RNA (mRNA) and protein
expression of BMPR2, Smad1, Id1, and Id3.20 Induction of phospho-
Smad1/5/8 and Id protein by BMP4 is also reduced in female hPASMCs,
and E2 decreased expression of Id genes in male hPASMCs. Under
certain conditions, platelet-derived growth factor (PDGF), E2, BMP4,
and serotonin induce proliferation only in non-PAH female hPASMCs,
consistent with decreased BMPR2 signaling and elevated pERK (phos-
phorylated extracellular signal-regulated kinase) expression in female
hPASMCs.20
E2 metabolism and PAH
Aberrant expression of CYP1B1 is reported in BMPR2 mutation–
affected female hPAH patients21,22 and hPASMCs isolated from IPAH
patients.23 A CYP1B1 SNP has also been identiﬁed that is in tight
linkage disequilibrium with SNPs associated with PH, suggesting that
these pathways may underpin sexual dimorphism in right ventricular
failure.24 CYP1B1 plays a key role in the development of PAH; there
is increased pulmonary artery CYP1B1 expression in PAH patients
and in animal models of PH.25 CYP1B1 expression is also elevated
in female SERT+mice and demonstrating PH.25 There is a therapeu-
tic effect of a CYP1B1 antagonist in four animal models of PAH: the
hypoxic mouse, the Sugen/hypoxic mouse, the SERT+ mouse, and the
dexfenﬂuramine-treated female mouse.25-27 In addition, a CYP1B1
antagonist markedly prolongs survival in the monocrotaline-treated
pulmonary hypertensivemale rat.27 This conﬁrms that CYP1B1-induced
metabolite accumulation likely contributes to the development of PAH.
Further, the E2 metabolite 16α-OHE1 is increased in the hypoxic
mouse, and 16α-OHE1-induced proliferation is greatest in hPASMCs
from PAH patients.25 It has recently been shown that 16α-OHE1
causes proliferation of hPASMCs via the receptor ERα.27 When ad-
ministered in vivo, 16α-OHE1 also caused PH in mice.25 This is con-
sistent with a role for this metabolite in the development of PAH.
Indeed, the 16α-OHE1 ∶ 2ME ratio was found to be high in hPAH
patients, and 16α-OHE1 suppressed BMP signaling in mice.21,28
High E2 signaling drives penetrance
The ﬁnding of an elevated 16α-OHE1 ∶ 2ME ratio in patients, includ-
ingmale patients, raises the question of whether this is correlation or
causation and, if it is causative, whether the issue is the high level of
16α-OHE1 or the low level of 2ME. In BMPR2-mutant mice, which
like PAH patients will spontaneously develop PAH but with reduced
penetrance, addition of 16α-OHE1 drives increased penetrance and
increased severity of disease, including greater vascular pruning.28 Con-
versely, increased 2ME is not protective in this model and may slightly
increase penetrance.28 This is because 16α-OHE1 is far more estro-
genic than 2ME; 16α-OHE1 binds the E2 receptors covalently, whereas
2ME is a weak agonist.29 These data support the hypothesis that in
PAH, increased estrogenicity is associated with increased disease pen-
etrance and severity.
Increased E2 signaling drives metabolic defects
The female preponderance of disease has been a bit of a paradox in
the past, because in classical rodent models of PAH, such as hypoxia
and monocrotaline, E2 was usually published as protective: it is vaso-
dilatory and anti-inﬂammatory, among other positive effects.30 How-
ever, these studies were all carried out in male rodents. The metabolite
16α-OHE1 is also anti-inﬂammatory in BMPR2-mutant mice;28 how-
ever, in addition to its effects in suppressing BMPR2 mentioned above,
it appears to independently cause signiﬁcant alterations in metabo-
lism onmany levels.
BMPR2-mutant cells treated with 16α-OHE1 have signiﬁcantly
decreased mobilization of the glucose transporter Glut4 in response
to insulin, associated with reductions in Glut4 protein, reductions in
lipid transporter CD36 protein, and reductions in the central metab-
olism regulator PPARγ (peroxisome proliferator–activated receptor
gamma) protein, among others.31 This is associated with increased
insulin resistance and decreased mitochondrial size in live animals.31
In multiple publications from groups in many different countries,
alterations in metabolism have been causally linked to PAH not just
in animal models but also in PAH patients.32,33 It is thus plausible that
E2’s impact on metabolism is causal for increased penetrance.
Note that these metabolic shifts are probably linked to a pro-
proliferative phenotype. These shifts result in outputs of the Krebs
cycle changing from energy to synthetic intermediates, allowing the
proliferation to continue. Thus, saying that E2 drives PAH through
shifts in metabolism is not at odds with saying that E2 drives PAH
through increasing proliferation. However, whether E2 drives pro-
liferation directly in the context of PAH has not been tested; con-
versely, E2 does appear to directly drive alteration in metabolism,
through regulation of miR29 (although possibly through other mech-
anisms as well).
E2 modulation of metabolism is at least partly
through induction of miR29
MicroRNAs (miRs) are short, single-stranded, non–protein-coding
gene products, typically 20–22 nucleotides long, that posttranscrip-
tionally regulate the expression of target genes through interactions
with speciﬁc mRNAs. E2-speciﬁc differential regulation of miRs in
BMPR2-mutant mice are well matched by differential regulation of
miRs in PAH patient lungs, as compared to control lungs or lungs
from idiopathic pulmonary ﬁbrosis patients.31In particular, on the ba-
sis of miR array data, although multiple miRs related to regulation of
metabolism show altered expression in both BMPR2-mutant mice
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and patients, all three isoforms of the miR29 family are strongly
upregulated in both.31
Blocking miR29 with an antagomiR results in rescue of PPARγ
protein expression, signiﬁcant reduction in penetrance of PAH in
BMPR2-mutant mice, normalization of insulin resistance, and re-
duction in accumulation of the toxic lipid ceramide in lung tissues.31
Moreover, in both live mice and tissue culture, blocking miR29 re-
sults in normalization of average mitochondrial size, suggesting a
return to more normal metabolic function.
Unfortunately, direct regulation of miR29 in patients to correct
metabolic problems may have barriers. Although miR29 is strongly
induced in PAH patients, it is strongly suppressed in idiopathic pul-
monary ﬁbrosis patients, and so correct titration of miR29 levels would
likely be critical to its use as a therapeutic tool.
E2 regulation of the 5-hydroxytryptamine 1B receptor
is via downregulation of miR96
The 5-hydroxytryptamine 1B (5HT1B) receptor mediates hPASMC
proliferation, and miR96 regulates the gene for the 5HT1B recep-
tor. Expression of miR96 is reduced in BMPR2R899X+/− PASMCs
from female mice and hPASMCs from female patients with PAH.34
This is associated with increased 5HT1B receptor expression and
serotonin-mediated proliferation, and this is driven by E2, which can
reduce miR96 expression34 and increase 5HT1B receptor expression.
Transfection of precursor miR96 into hPASMCs reduces 5HT1B re-
ceptor expression and inhibits serotonin-inducedproliferation.34,35 Res-
toration of miR96 expression in pulmonary arteries in vivo via admin-
istration of a miR96 mimic reduces 5HT1B receptor expression and
the development of hypoxia-induced PH in the mouse.34
MAPK SIGNALING
The MAPK pathways consist of evolutionarily conserved kinases,
including extracellular signal–regulated kinase (ERK1/2), p38 MAPK,
and c-Jun NH2-terminal kinase (JNK). These 3-tiered MAPK mod-
ules (Fig. 2) receive and integrate extracellular or intracellular stimuli,
phosphorylating downstream targets to regulate fundamental cellular
processes, including proliferation, differentiation, metabolism, migra-
tion, survival, and apoptosis.36,37 Despite an increase in the number
of publications describing dysregulated MAPK signaling in PAH,
the role of altered MAPK activation in the development and/or
progression of PAH is incompletely deﬁned. A better understanding
of these complex signaling cascades and their inﬂuence on pulmonary
vascular remodeling in PAH is necessary to determine whether these
pathways are promising therapeutic targets. This section focuses on
the roles of Raf/ERK1/2 and p38 MAPK signaling in PAH.
Dysregulated Raf/ERK signaling in PAH
ERK1/2 signaling is activated in response to growth factor and mi-
togen binding to their cognate RTKs, such as vascular endothelial
growth factor receptor (VEGFR), ﬁbroblast growth factor receptor
(FGFR), and PDGF receptor (PDGFR). Through parallels with can-
cer pathobiology, RTKs and their downstream signaling cascades have
been linked to pulmonary vascular remodeling in PAH.38-40 More
than a decade ago, Tuder et al.3 demonstrated endothelial expression
of VEGF and VEGFR within plexogenic lesions in lung specimens
from PAH patients. The implications of this ﬁnding, however, still
remain unclear. Partovian et al.41 reported that overexpressing VEGF
protected against hypoxia-induced PAH by improving endothe-
lial function, and Taraseviciene-Stewart et al.42 demonstrated VEGFR
blockade in combination with hypoxia-induced PAH in rats. One ex-
planation for this unexpected ﬁnding is that pharmacological inhi-
bition of VEGFRs results in upregulation of other RTKs. A detailed
review by Voelkel and Gomez-Arroyo43 highlights the complexity
of VEGF signaling in PAH. This paradoxical effect of activating RTKs
by blocking others may also explain the differences between two
PDGFR inhibitors, imatinib and dasatinib. Imatinib, an RTK in-
hibitor used to treat chronic myelogenous leukemia, reversed both
monocrotaline-induced PH and PH induced by chronic hypoxia.38
Phase 244 and 345 trials of imatinib have yielded some evidence of
efﬁcacy in PAH but have also raised concerns about adverse effects
because of a substantial incidence of subdural hematoma. In stark
contrast, precapillary PH has developed in patients receiving da-
satinib for imatinib-resistant chronic myelogenous leukemia.46 The
proﬁle of targets for dasatinib shows a range of RTKs broader than
that for imatinib, including RTKs that regulate focal adhesions and
Figure 2. Mitogen-activated protein kinase (MAPK) signaling path-
ways. Simpliﬁed schematic depicting the activation of ERK1/2 (extra-
cellular signal-regulated kinases), JNK (c-Jun NH2-terminal kinase),
and p38 MAPK after growth factor–, cytokine-, and/or environmen-
tal stress–mediated phosphorylation of MAP3 kinases (MAP3K) fol-
lowed by the phosphorylation and activation of MAP2 kinases (MAP2K).
Growth factor–induced receptor tyrosine kinase (RTK) activation re-
sults in the subsequent activation of the Raf/MEK/ERK pathway.
Growth factors can also mediate the activation of JNK through he-
matopoietic progenitor kinase (HPK), which phosphorylates MKK4
(mitogen-activated protein kinase kinase 4). Stress-dependent ac-
tivation of ASK1 (apoptosis signal regulating kinase 1) also targets
the MKK4/JNK pathway in addition to MKK3/p38 MAPK. TGFBR1
(transforming growth factor beta receptor 1)-induced activation of
TAK1 (TGF-β-activated kinase 1) and ultraviolet radiation–induced
RAC1 and/or CDC42 activation results in the activation of both JNK
and p38MAPK.
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the cytoskeleton.46 These studies highlight the signiﬁcance of tar-
geting RTKs in PAH, but further study of their effects on the down-
stream Ras/Raf/MEK signaling pathway may provide the necessary
insight to develop safer therapies.
The Ras/Raf/MEK signaling cascade links upstream RTK to
ERK1/2 activation47 and is implicated in carcinogenesis, with 30%
of all cancers showing dysregulated MAPK signaling due to muta-
tions in Ras and Raf.48 Aberrant ERK activation has been described
in the pulmonary vasculature of patients with advanced PAH, im-
plicating upstream activation of Ras/Raf/MEK in disease pathogene-
sis.49 Evidence that Ras/Raf/MEK activation plays an important role
in pulmonary vascular responses to injury/stress comes from Raf-1
kinase inhibitor protein knockout mice that suffer from exaggerated
hypoxia-induced PH as a result of the failure to inhibit MEK1/2 phos-
phorylation by Raf-1.50 The identiﬁcation of Raf-1 gain-of-function
mutations (p.Ser257Leu) leading to constitutive activation of the Raf/
MEK/ERK1/2 pathway51 in 2 infants who developed severe PAH fur-
ther implicates Raf/ERK dysregulation in PAH.52
Loss-of-function mutations in BMPR2 are the most common
genetic cause of PAH, accounting for 70% of familial cases53 and
10%–40% of IPAH.54,55 Despite variable impact on canonical BMP/
Smad signaling, PAH-associated BMPR2 mutations uniformly acti-
vate MAPK pathways.49,56 Importantly, BMPR2 expression is mark-
edly reduced in end-stage PAH, even in patients not harboring mu-
tations,57 underscoring the relevance of BMPR2-mediated regulation
of MAPK signaling to the development of PAH. In BMPR2-silenced
pulmonary artery endothelial cells (PAECs), we reported constitutive
activation of Raf family members as well as ERK1/2. Two Raf in-
hibitors, sorafenib and AZ628, and a triple angiokinase inhibitor,
nintedanib, decreased ERK1/2 activation and reversed the abnor-
mal proliferation and hypermotility of BMPR2 deﬁciency,58 suggest-
ing that inhibition of dysregulated Ras/Raf/ERK signaling may be use-
ful in reversing vascular remodeling in PAH.
p38 MAPK contributes to the hyperproliferative
and inflammatory PAH phenotype
Environmental stressors, as well as inﬂammatory cytokines, activate
the p38 MAPK pathway through phosphorylation by MKK3 and
MKK6. Independent of MAPK kinases, p38 MAPK is also activated
through a direct interaction with TAB1 (TAK-1 binding protein)59
and subsequent phosphorylation by AMPK (AMP-activated protein
kinase).60 Activation of p38 MAPK has been shown to have detri-
mental effects on endothelial function and is linked to many diseases,
including cardiac hypertrophy61 and heart failure.62 In PAH, Ruda-
rakanchana et al.56 demonstrated that the overexpression of BMPR2
mutants resulted in increased proliferation mediated by p38 MAPK
activation. The increased growth of SMCs derived from PAH pa-
tients was reported by Wilson et al.63 to be caused by the activation
of p38 MAPK and JNK. Serotonin, a potent mitogen implicated in
the pathogenesis of PAH,64 activated p38 MAPK and increased the
proliferation of pulmonary artery ﬁbroblasts exposed to hypoxic con-
ditions.65 Pharmacological inhibition of p38 MAPK in rat pulmonary
artery ﬁbroblasts exposed to chronic hypoxia66 or in the monocrota-
line rat model of PH67 blocked hypoxia-induced proliferation.
In addition to its proproliferative effects, p38 MAPK activation
also triggers inﬂammatory signaling cascades. Inﬂammation is increas-
ingly recognized as playing a central role in PAH pathobiology.68-70
In IPAH, serum levels of the inﬂammatory mediator inerleukin-6
(IL-6) were signiﬁcantly higher than those in controls,71 and mice
deﬁcient in IL-6 exposed to hypoxia showed decreased SMC mi-
gration and macrophage recruitment in the lungs compared to wild-
type mice.72 Inhibition of p38 MAPK decreases IL-6 expression and
reverses both chronic hypoxia– and monocrotaline-induced PAH,
indicating that pulmonary vascular remodeling is due partly to p38
MAPK activation.67
Importantly, dysregulated MAPK signaling has been observed in
various experimental models of PAH and in PASMCs from patients
with BMPR2 mutations and is a prominent consequence of BMPR2
silencing in PAECs. Taken together, there is mounting evidence sug-
gesting a central role for MAPK signaling in the proliferative and
inﬂammatory PAH phenotype. A better understanding of these sig-
naling pathways is essential for the design of safer and more effec-
tive therapies.
WNT SIGNALING PATHWAYS: KEY PLAYERS
IN THE PRESERVATION OF PULMONARY
VASCULAR HOMEOSTASIS
Similar to the p38 signaling pathways, Wnt pathways are respon-
sible for regulating baseline cellular activities involved in the pres-
ervation of homeostasis and in response to environmental stress-
ors.73 Wnt signaling is the term used to describe a superfamily of
evolutionarily conserved signaling pathways whose activity is in-
dispensable for proper embryonic development and regeneration of
damaged tissues in postnatal life. A common thread in Wnt signal-
ing is the interaction of Wnt ligands with surface receptors that
trigger unique signaling events with speciﬁc biological consequences
related to the speciﬁc Wnt pathway involved. The best-characterized
(i.e., “canonical”) of the Wnt signaling pathways is the Wnt/β-catenin
(βC) pathway, known for targeting βC, a dynamic cytoplasmic pro-
tein that responds to ligand-receptor binding by relocating to the
nucleus and modulating gene expression (Fig. 3A). In steady state,
βC is bound to a cytoplasmic complex composed of axin, adenoma-
tous poliposis coli (APC), and glycogen synthase kinase 3β (GSK3β),
responsible for directing βC away from the nucleus and into pro-
teasomal complexes.74 However, when Wnt ligands bind to a recep-
tor complex composed of a member of the frizzled (FZD) family of
receptors and the low-density lipoprotein receptor–related protein
(LRP) 5/6, the cytoplasmic protein disheveled (Dvl) is activated,
which then shuts down the βC degradation complex. Once released
from the complex, βC translocates to the nucleus, where it targets
the transcription of genes responsible for controlling cell fate, pro-
liferation, and survival.75 Gain or loss of Wnt/βC activity is a fea-
ture of a wide range of clinical diseases, such as cancer, stroke, and
heart failure; this has led to ongoing efforts to exploit opportunities
to develop Wnt-based biomarkers and therapeutic strategies for many
of these diseases.76,77
Besides the Wnt/βC pathway, there are other Wnt pathways
that have more specialized biological functions and whose activation
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is independent of βC accumulation. Among these “noncanonical”
Wnt pathways, Wnt/PCP signaling is responsible for regulating cell
movements during tissue morphogenesis. In mammals, activation of
Wnt/PCP is necessary for neural-tube closure, and mutations that
disrupt this event result in neural-tube defects, such as craniora-
chischisis and spina biﬁda.78 In contrast to Wnt/βC, recruitment of
other coreceptors, such as receptor tyrosine kinase-like orphan re-
ceptor 2 (ROR2), is necessary to activate the pathway (Fig. 3B). Once
again, the protein Dvl is activated, but in this case, it is responsible
for activating the small GTPases Rac, Rho, and cdc42, which pro-
voke cytoskeletal rearrangements that allow cells to navigate their
immediate environment and synchronize their movements to those
of other cells within a speciﬁc tissue plane.79,80 Like that of Wnt/βc,
dysregulation of Wnt/PCP is a feature of various disorders, such as
cancer, where it appears to contribute to progression and metasta-
sis, thus making Wnt/PCP an attractive ﬁeld for the development of
novel therapeutics.
A study examining the expression proﬁle of laser-microdissected
plexiform lesions demonstrated signiﬁcant upregulation of PCP path-
way genes such as Wnt11, Rho, and Dvl.81 This was the ﬁrst indica-
tion that Wnt signaling may play a role in PAH. A signaling crosstalk
between the BMP and Wnt signaling pathways was shown to be
partially responsible for the protective effects of BMP on the pulmo-
nary endothelium. BMP2 triggers βC activation independent of Wnt
ligand stimulation to upregulate genes such as VEGF-A, survivin, and
cyclin D1 and induce proliferation and survival of PAECs. Down-
regulation of BMPR2 resulted in loss of βC activation, which signif-
icantly compromised the capacity of BMP2 to protect the cell against
serum starvation and impair regeneration of PAECs lost to apoptosis.
Concomitant to βC activation, BMPR2 also triggers PAEC motility
in response to BMP2 by downstream activation of RhoA and Rac1,
the signaling mediators of the Wnt/PCP pathway. Compromising
activation of either βC or RhoA/Rac1 in PAECs, in an in-vivo ma-
trigel plug angiogenesis model, prevented BMP2-induced angiogene-
sis, leading to a signiﬁcant reduction of functional blood vessels.82
These observations suggest that concomitant activation of both Wnt
signaling pathways is necessary for preservation of pulmonary vascu-
lar homeostasis and that loss of either Wnt pathway could contribute
to PAH by limiting the extent of vascular regeneration in response
to injury.
Lung pathology has shown that vascular remodeling is in great
part caused by accumulation of PASMC-like cells in the neointima
and media of small pulmonary arteries. BMP2 also activates both
Wnt/βC and Wnt/PCP in PASMCs, but the order in which the path-
ways are activated differs from that observed in PAECs. As its ﬁnal
outcome, this chain of events can, in response to a vascular insult, mo-
bilize PASMCs to reach the damage zone and aid in tissue repair
while it prevents their accumulation by suppressing βC-dependent
growth. The consequences of interfering with this protective signal-
ing mechanism were shown in an in-vivo carotid stent model, where
a mutant Dvl construct was found to result in severe neointima for-
mation and medial thickening from PASMC accumulation.10 Con-
sistent with this, PAH PASMCs (isolated from human PAH lungs
obtained through the Pulmonary Hypertension Breakthrough Ini-
tiative) demonstrate increased baseline levels of active βC that cor-
related with their known proproliferative and apoptosis-resistant
phenotype, and reduction of endogenous βC levels with small inter-
fering RNA partially normalized growth and survival response. In-
triguingly, application of Wnt5a (a ligand known to trigger Wnt/
PCP signaling) was able to suppress βC levels in healthy PASMCs
but not in PAH PASMCs.83 This suggests the existence of a cross-
talk between Wnt/βC and Wnt/PCP that is responsible for appro-
priate PASMC response to injury regulation, which could be dysfunc-
tional in PAH and contribute to the aberrant behavior of PASMCs
in the disease.
More recently, a key role has been identiﬁed for Wnt/PCP in the
assembly of the pulmonary microcirculation, orchestrating the es-
tablishment of endothelial-pericyte interactions during late angio-
genesis. Pericytes are mural cells that provide structural support to
capillaries and act as a source of cytokines that enhance endothelial
viability and vessel maturation; absence of appropriate pericyte cov-
erage can result in capillary fragility, endothelial cell apoptosis, and
loss of microvessels.84-86 With matrigel-based coculture assays, it was
shown that pericytes puriﬁed from explanted PAH lungs fail to reach
healthy PAECs during tube assembly, resulting in tube networks
smaller than healthy donor samples. In addition, Wnt/PCP genes friz-
Figure 3. The Wnt signaling pathways regulate gene expression and
cell movements. The Wnt/βC pathway (A) controls gene expression
through DVL-dependent activation and nuclear shuttling of βC, while
Wnt/PCP (B) modulates motility, polarity, and tissue morphogenesis
thru DVL activation of RhoA/Rac1/cdc42. Speciﬁc domains within
Dvl are responsible for differentia activation of βC (DIX) or PCP
(PDZ/DEP). βC: β-catenin; DVL: protein disheveled; FZD: frizzled
family of receptors; GSK3: glycogen synthase kinase 3; LRP: low-
density lipoprotein receptor–related protein; PCP: planar cell polar-
ity; ROR2: receptor tyrosine kinase-like orphan receptor 2.
290 | Novel signaling pathways in PAH Awad et al.
This content downloaded from 130.209.115.202 on November 03, 2016 07:43:56 AM
All use subject to University of Chicago Press Terms and Conditions (http://www.journals.uchicago.edu/t-and-c).
zled 7 (Fzd7) and CDC42 were signiﬁcantly downregulated in PAH
pericytes and correlated with lower response to Wnt5a stimulation.
Knockdown of both Fzd7 and CDC42 in healthy lung pericytes re-
produced the abnormal PAH pericyte phenotype both in vitro and
in an in-vivo matrigel plug assay, whereas restoring their expres-
sion in PAH pericytes resulted in increased association with endo-
thelial cells and larger tube networks.87
Taken together, these studies suggest a model in which both
Wnt/βC and Wnt/PCP participate in regeneration of pulmonary
microvessels by promoting angiogenesis in response to injury (Fig. 4).
The data suggest that gene mutations in BMPR2 and dysregulation
of Wnt gene expression can contribute to impaired angiogenesis, and
disruption could serve as future therapeutic targets for addressing
defective angiogenesis and abnormal vascular remodeling in PAH.
SUMMARY
This review discusses novel signaling pathways in PAH, including
estrogenic, MAPK, and Wnt signaling pathways. Female sex and
sex hormones are risk factors for developing PAH. Endogenous E2
and E2 metabolites are pathogenic in the pulmonary circulation, and
regulation may be controlled by miRAs. The metabolite 16α-OHE1
may regulate miR29, which modulates energy metabolism. E2 can
decrease miR96 expression, leading to upregulation of the 5HT1B
receptor, increasing serotonin-induced proliferation in female PASMCs.
Figure 4. Proposed role of Wnt signaling in pulmonary vascular homeostasis. A, Wnt/βC and Wnt/PCP coordinate endothelial growth
and movement during vascular repair in response to injury. B, Loss of Wnt signaling results in impaired angiogenesis and is permissive to
PASMC-driven obliterative vasculopathy. βC: β-catenin; PASMC: pulmonary artery smooth muscle cell; PCP: planar cell polarity.
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E2 can also inhibit BMPR2 expression and BMP signaling. Overall,
in both humans and genetic mouse models of PAH, higher E2 sig-
naling results in increased pulmonary vascular injury and higher PAH
penetrance. These data suggest that inhibition of estrogenic signal-
ing, either directly or through targeting intermediates, may be a viable
therapeutic strategy in PAH.
Other viable therapeutic targets in PAH include MAPK and Wnt
signaling pathways. Targeting these pathways may decrease prolifer-
ation, inﬂammation, and angiogenesis. The constitutive activation of
Raf/ERK and p38 MAPK pathways results in increased proliferation
of pulmonary cells and inﬂammation. Although inhibition of these
pathways in animal models demonstrates some reversal of pulmo-
nary hypertension, phase 2 and 3 trials of imatinib reported severe
adverse side effects due to off-target effects. Dysregulation of Wnt
pathways may contribute to pathogenesis in PAH, cancer, and heart
failure. The Wnt pathway inﬂuences BMP2-induced angiogenesis,
and loss of Wnt signaling results in severe pulmonary neointima
formation, medial thickening, and impaired pulmonary vascular re-
generation in response to injury. A clearer understanding of these
intricate pathways will help in the development of safer and more
effective therapies for PAH.
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